Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 7Colorectal Neoplasms 4Stomach Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Meningeal Neoplasms 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Radiotherapy 22Fluorouracil 20Oxaliplatin 19Leucovorin 14Cisplatin 14Paclitaxel 10Radiation 8Irinotecan 8Docetaxel 7Capecitabine 7Cetuximab 6Carboplatin 6pembrolizumab 5Neoadjuvant Therapy 5Trastuzumab 4Taxes 4Chemotherapy, Adjuvant 4Panitumumab 3Microarray Analysis 3Immunohistochemistry 3Folfox protocol 3Epirubicin 3Biopsy 3tucatinib 2Surgical Procedures, Operative 2Reverse Transcriptase Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma Of Esophagus × tucatinib × Clear all
NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed
17 enrolled 23 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡